Durvalumab Monotherapy in Complex Advanced Hepatocellular Carcinoma: A Real‐World Study of Patients Ineligible for Combination Immunotherapy

Documenti analoghi

• Cytokine release syndrome following durvalumab and tremelimumab in advanced hepatocellular carcinoma: A case report with cytokine and damage‐associated molecular pattern analysis
  di: Tomomi Ozaki, et al.
  Pubblicazione: (2024)
• Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post‐Progression Outcomes: A Multicenter Real‐World Study in Advanced Hepatocellular Carcinoma
  di: Masanori Inoue, et al.
  Pubblicazione: (2026)
• Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
  di: Tomomitsu Matono, et al.
  Pubblicazione: (2025)
• Effect of Butyrate‐Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab
  di: Kazuhiro Nouso, et al.
  Pubblicazione: (2026)
• Efficacy and Safety of Atezolizumab Plus Bevacizumab Versus Durvalumab Plus Tremelimumab for Unresectable Hepatocellular Carcinoma in Patients With Child–Pugh Class B: A Real‐World Study
  di: Hideko Ohama, et al.
  Pubblicazione: (2026)